Premium
Cardiovascular disease in hereditary haemophilia: The challenges of longevity
Author(s) -
Shapiro Susan,
Benson Gary,
Evans Gillian,
Harrison Catherine,
Mangles Sarah,
Makris Mike
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18085
Subject(s) - medicine , haemophilia , life expectancy , antithrombotic , disease , coronary artery disease , atrial fibrillation , stroke (engine) , secondary prevention , population , longevity , intensive care medicine , pediatrics , gerontology , mechanical engineering , environmental health , engineering
The development of effective and safe treatments has significantly increased the life expectancy of persons with haemophilia (PWH). This has been accompanied by an increase in the comorbidities of ageing including cardiovascular disease, which poses particular challenges due to the opposing risks of bleeding from haemophilia and antithrombotic treatments versus thrombosis. Although mortality secondary to coronary artery disease in PWH is less than in the general population, the rate of atherosclerosis appears similar. The prevalence of atrial fibrillation in PWH and risk of secondary thromboembolic stroke are not well established. PWH can be safely supported through acute coronary interventions but data on the safety and efficacy of long‐term antithrombotics are scarce. Increased awareness and research on cardiovascular disease in PWH will be crucial to improve primary prevention, acute management, secondary prevention and to best support ageing PWH.